Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, Yesterday

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.

Off-pump CABG tied to higher mortality in patients with left main disease

13 Aug 2019

Off-pump, compared with on-pump, coronary artery bypass grafting (CABG) in patients with left main disease results in a lower rate of revascularization of the coronary arteries supplying the inferolateral wall and an increased risk of 3-year all-cause death, results of the EXCEL* trial have shown.

Of the 923 CABG patients, 652 underwent on-pump surgery and 271 off-pump. The extent of disease was similar between the two groups, but patients in the off-pump arm had a lower rate of revascularization of the left circumflex coronary artery (84.1 percent vs 90.0 percent; p=0.01) and right coronary artery (31.1 percent vs 40.6 percent; p=0.007).

After inverse probability of treatment weighting (IPTW) adjustment for baseline difference, an association was found between off-pump surgery and a significant increase in the risk of 3-year all-cause death (8.8 percent vs 4.5 percent; hazard ratio [HR], 1.94, 95 percent CI, 1.10–3.41; p=0.02), as well as a nonsignificant difference in the risk for the composite endpoint of death, myocardial infarction or stroke (11.8 percent vs 9.2 percent; HR, 1.28, 0.82–2.00; p=0.28).

The EXCEL trial compared percutaneous coronary intervention with everolimus-eluting stents with CABP in patients with left main disease. CABG was performed with or without cardiopulmonary bypass (on-pump vs off-pump surgery) according to the discretion of the operator. IPTW for treatment effect estimation was used to compare the 3-year outcomes in the off-pump and on-pump groups.

“Concerns remain for a greater risk of incomplete revascularization and reduced survival with off-pump CABG surgery compared with on-pump surgery particularly in patients with left main disease and extensive underlying myocardial ischaemia,” the authors said.

*Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Cardiology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
07 Sep 2019
Eating mushrooms has no correlation with biomarkers and risks of cardiovascular disease (CVD) and type 2 diabetes (T2D) in adults, a US study has shown.
03 Sep 2019
Sleep apnoea is highly prevalent but largely undetected in the general population of middle-aged adults, with a symptom-based strategy proving to be useless for specific diagnosis, according to a recent study. Moreover, mild sleep apnoea represents a higher-risk phenotype with manifestly increased metabolic, inflammatory and cardiovascular risk factor burden, with potential public health implications.
Rachel Soon, Yesterday

Adding simvastatin as an adjuvant to standard triple therapy in Helicobacter pylori treatment may help compensate for increasing antimicrobial resistance, according to a new study.

Christina Lau, 03 Sep 2019
The sodium-glucose co-transporter 2 (SGLT2) inhibitor dapagliflozin significantly reduces the risk of death and hospitalization in patients with heart failure (HF) with reduced ejection fraction (rEF) regardless of whether they have type 2 diabetes mellitus (T2DM), the DAPA-HF trial has shown.